JVS Diagnostics: A test for early detection of breast cancer

The main articles are:

• Cancer diagnosis
• Breast cancer (BC)

2022: Method Representation

The development of the Skolkovo resident will help detect breast cancer in the early stages. The Skolkovo Foundation announced this on August 2, 2022.

The study shows that the use of a combination of cancer markers in the early stages of breast cancer avoids false positive results. The company plans to introduce improved testing in medical centers in Moscow and St. Petersburg.

The proposed testing could substantially simplify the breast cancer screening procedure early on through a blood test. Scientists note that the use of an additional marker CA15-3 gives the Jayvis Diagnostics decision specificity (at the level of 100%) to the localization of cancer and avoids false positive results, obtain 75% sensitivity at the zero and first stages of cancer. This is more than twice the results obtained in the framework of studies of circulating DNA. Research was carried out on a grant from the Skolkovo Foundation in the amount of 30 million rubles.

The Jayvis Diagnostics team set an ambitious goal to create a test for early detection of cancer. The Skolkovo Foundation sees that the task is being solved successfully. We believe that the introduction into the structure of practical health care will be on the back of the company, said Sergey Shcherbakov, project manager of the Skolkovo Foundation Biomedical Technology Cluster.

The work, published by the leading international journal Cancer Biomarkers on June 23, 2022, highlighted part of the results of a blind clinical study conducted in conjunction with Sechenov University.

Jayvis Diagnostics continues to introduce the developed method into medical practice together with Sechenov University and develops the capabilities of the decision system on the localization of the tumor by doctors based on the results obtained as part of testing, noted Zhanneta Cherkasova, CEO of Jayvis Diagnostics.

The launch of the SA-62 oncotest is planned on a commercial basis through medical centers and clinics, first in Moscow and St. Petersburg in the form of a package of checks for the absence of cancer. In the future, it will be possible to make an analysis for the level of an oncomarker independently through federal networks, including as part of voluntary health insurance.